The Fibrin Assay Comparison Trial (FACT): Correlation of Soluble Fibrin Assays with D-dimer

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Thrombosis and Haemostasis

• Publication date

  2001-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0037-1616052PMID 11816708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Sequence y-( 312-324 ) Is a Fibrin-Specific Epitope

  2003cited by this paper
• The Fibrin Assay Comparison Trial (FACT)

  2001influential reference
• Thrombin-activable Fibrinolysis Inhibitor Attenuates (DD)E-mediated Stimulation of Plasminogen Activation by Reducing the Affinity of (DD)E for Tissue Plasminogen Activator

  2000cited by this paper
• An Integrated Study of Fibrinogen during Blood Coagulation*

  1999cited by this paper
• A Soluble Fibrin Standard: Comparable Dose-response with Immunologic and Functional Assays

  1999cited by this paper
• The Use of Soluble Fibrin in Evaluating the Acute and Chronic Hypercoagulable State

  1999cited by this paper
• Evaluation of the Factors Contributing to Fibrin–dependent Plasminogen Activation

  1998cited by this paper
• Fibrin Detected in Plasma of Patients with Disseminated intravascuiar Coagulation by Fibrin-specific Antibodies Consists Primarily of High Molecular Weight Factor XIIIa-crosslinked and Plasmin-modified Complexes Partially Containing Fibrinopeptide A

  1997cited by this paper
• A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma.

  1996cited by this paper
• Thrombus precursor protein (TpP): marker of thrombosis early in the pathogenesis of myocardial infarction.

  1996cited by this paper
• Stimulating effect on tissue-type plasminogen activator--a new and sensitive indicator of denatured fibrinogen.

  1995cited by this paper
• Comparison of Immunological and Functional Assays for Measurement of Soluble Fibrin

  1995cited by this paper
• Fibrin degradation product (FnDP) assays: analysis of standardization issues and target antigens in plasma

  1995cited by this paper
• Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.

  1993influential reference
• A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo.

  1993cited by this paper
• A monoclonal antibody which recognises an epitopic region unique to the intact fibrin polymeric structure

  1993cited by this paper
• A Rapid Monoclonal Antibody-Based Enzyme Immunoassay (EIA) for the Quantitative Determination of Soluble Fibrin in Plasma

  1992cited by this paper
• The sequence gamma-(312-324) is a fibrin-specific epitope.

  1991cited by this paper
• The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation.

  1990influential reference
• The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies.

  1989cited by this paper
• Factor XIIIa formation promoted by complexing of alpha-thrombin, fibrin, and plasma factor XIII.

  1987cited by this paper
• Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator.

  1986cited by this paper
• Determination of Soluble Fibrin in Plasma by a Rapid and Quantitative Spectrophotometric Assay

  1986cited by this paper

• Advances in D-dimer testing: progress in harmonization of clinical assays and innovative detection methods

  2024cites this paper
• Immunoreactivity of canine, feline, and equine D‐dimer with antibodies to human D‐dimer

  2023cites this paper
• D-dimer testing: A narrative review.

  2023cites this paper
• Formation and elimination of soluble fibrin and D-dimer in the bloodstream

  2023cites this paper
• D-dimer Testing in Pulmonary Embolism with a Focus on Potential Pitfalls: A Narrative Review

  2022cites this paper
• Is it possible to make a common reference standard for D‐dimer measurements? Communication from the ISTH SSC Subcommittee on Fibrinolysis

  2021cites this paper
• Coagulación intravascular diseminada

  2021cites this paper
• Diagnostic accuracy of D-dimer to detect left atrial thrombus in patients with atrial fibrillation: a systematic review and meta-analysis.

  2021cites this paper
• Coagulación intravascular diseminada

  2021cites this paper
• New diagnostic approaches for venous thromboembolism and thrombophilia

  2020cites this paper
• Age-adjusted D-dimer thresholds in the investigation of suspected pulmonary embolism: A retrospective evaluation in patients ages 50 and older using administrative data.

  2018cites this paper
• D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications

  2018cites this paper
• Plasma fibrin D-dimer and the risk of left atrial thrombus: A systematic review and meta-analysis

  2017cites this paper
• HOMOCYSTEINE, SOLUBLE FIBRIN AND D€“DIMER LEVELS IN CEREBROVASCULAR ACCIDENTS

  2016cites this paper
• D-Dimer as a prognostic marker of morbidity and mortality among HIV patients: a call for attention

  2016cites this paper
• D-dimer: An Overview of Hemostasis and Fibrinolysis, Assays, and Clinical Applications.

  2015cites this paper
• Evaluation of the Innovance d-Dimer Assay for the Diagnosis of Disseminated Intravascular Coagulopathy in Different Clinical Settings

  2014cites this paper
• New Combinational Assay Using Soluble Fibrin and D-Dimer Determinations: A Promising Strategy for Identifying Patients with Suspected Venous Thromboembolism

  2014cites this paper
• The clinical utility of fibrin-related biomarkers in sepsis

  2013cites this paper
• Auswirkung von niedrig dosiertem Hydrokortison auf die Gerinnungsparameter bei Patienten im septischen Schock

  2013cites this paper
• Çíà÷åíèå Ä-äèìåðà â äèàãíîñòèêå è ïðîãíîçå òðîìáîýìáîëè÷åñêèõ îñëîæíåíèé ó êàðäèîëîãè÷åñêèõ áîëüíûõ

  2012cites this paper
• Low plasma concentrations of coagulation factors II, VII and XI indicate increased risk among elderly with symptoms of heart failure

  2010cites this paper
• Factor V Leiden mutation and pregnancy. Haemostasis during pregnancy in non-carriers and carriers of factor V Leiden mutation, with special emphasis on placenta-mediated and venous thromboembolic complications and on blood coagulation and fibrinolysis markers for prediction of complications

  2009cites this paper
• Factor V Leiden mutation and pregnancy

  2009cites this paper
• Guidelines for the diagnosis and management of disseminated intravascular coagulation

  2009cites this paper
• Gerinnungsdiagnostik

  2008cites this paper
• Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.

  2007cites this paper
• Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation.

  2007cites this paper
• The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage

  2007cites this paper
• Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study

  2007cites this paper
• Elevated levels of soluble fibrin or D‐dimer indicate high risk of thrombosis

  2006cites this paper
• D-dimer assays: the current status and new assay technologies.

  2006cites this paper
• Back to the future: testing in disseminated intravascular coagulation

  2005cites this paper
• The performance of quantitative D-dimer assays in laboratory routine

  2005cites this paper
• Fibrin D-Dimer and Cardiovascular Risk

  2005cites this paper
• Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.

  2004cites this paper
• Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure

  2004cites this paper
• Soluble Fibrin, C-Reactive Protein, Fibrinogen, Factor VII, Antithrombin, Proteins C and S, Tissue Factor, D- Dimer, and Prothrombin Fragment 1 2 in Men With Acute Myocardial Infarction <45 Years of Age

  2004cites this paper
• Gerinnungsdiagnostik

  2004cites this paper
• Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction </=45 years of age.

  2004cites this paper
• D-Dimer Testing for Suspected Pulmonary Embolism: Performance of Two Rapid Quantitative Assays

  2004cites this paper
• Course of indicators of thrombin activity in the early phase of acute myocardial infarction: effect of fibrinolytic therapy and acute percutaneous coronary angioplasty

  2003cites this paper
• Current Clinical Practice DIC 2002: A Review of Disseminated Intravascular Coagulation

  2003cites this paper
• DIC 2002: A Review of Disseminated Intravascular Coagulation

  2003cites this paper
• Utilisation en pratique des marqueurs biologiques de la coagulation et de la fibrinolyse

  2002cites this paper
• Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease

  2002cites this paper
• Clinical Report D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation

  2002cites this paper
• D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation.

  2002cites this paper